Quantinno Capital Management LP Raises Stock Holdings in Amedisys, Inc. (NASDAQ:AMED)

Quantinno Capital Management LP grew its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 48.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 59,911 shares of the health services provider’s stock after acquiring an additional 19,454 shares during the quarter. Quantinno Capital Management LP’s holdings in Amedisys were worth $5,439,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of AMED. Blue Trust Inc. raised its stake in Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after purchasing an additional 124 shares in the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Amedisys in the 4th quarter worth about $55,000. Vestcor Inc purchased a new stake in shares of Amedisys during the 4th quarter valued at about $73,000. Venturi Wealth Management LLC lifted its holdings in shares of Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock valued at $89,000 after acquiring an additional 779 shares during the last quarter. Finally, Covestor Ltd grew its position in Amedisys by 48.8% in the fourth quarter. Covestor Ltd now owns 1,037 shares of the health services provider’s stock worth $94,000 after acquiring an additional 340 shares in the last quarter. 94.36% of the stock is owned by hedge funds and other institutional investors.

Amedisys Price Performance

AMED stock opened at $94.62 on Friday. The stock has a market cap of $3.11 billion, a PE ratio of 37.55, a P/E/G ratio of 1.78 and a beta of 0.96. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95. The company has a 50-day moving average price of $93.22 and a 200 day moving average price of $91.63. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.12. The business had revenue of $594.78 million during the quarter, compared to the consensus estimate of $597.43 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.03 earnings per share. Equities research analysts anticipate that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on AMED. Stephens restated an “equal weight” rating and set a $101.00 price objective on shares of Amedisys in a research report on Tuesday, March 4th. Royal Bank of Canada reissued an “outperform” rating and set a $100.00 target price on shares of Amedisys in a research report on Wednesday, April 16th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.